Health Affairs, 25, no. 5 (2006): 1231-1239 doi: 10.1377/hlthaff.25.5.1231 © 2006 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Full Text (HTML) Reprint (PDF) Erratum Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Carino, T. Articles by Bridger, P. Search for Related Content PubMed PubMed Citation Articles by Carino, T. Articles by Bridger, P. Related Collections Access To Care Insurance Coverage Managed Care - Medicare Medicare Business Of Health Pharmaceuticals Research And Technology Health Spending Consumer Issues Insurance Market Evidence-Based Medicine

Coverage

Medicare’s Coverage Of Colorectal Cancer Drugs: A Case Study In Evidence Development And Policy

Payers point to the lack of unbiased evidence for making coverage decisions for new and often costly technologies. This paper provides a case study of a new approach to developing information to meet the needs of a payer: Medicare’s coverage with evidence development (CED) policy. Medicare’s decision to condition coverage of cancer therapies on clinical trial participation is an early application of CED and signals Medicare’s interest in developing evidence on new technologies for beneficiaries. This paper reviews the rationale and challenges Medicare faces in applying its CED policy and discusses the implications of payers’ using and generating evidence.

                      What's this?

This article has been cited by other articles:

				P. J. Neumann, M. S. Kamae, and J. A. Palmer Medicare's National Coverage Decisions For Technologies, 1999-2007 Health Aff., November 1, 2008; 27(6): 1620 - 1631. [Abstract] [Full Text] [PDF]

				R. F. Redberg Evidence, Appropriateness, And Technology Assessment In Cardiology: A Case Study Of Computed Tomography Health Aff., January 1, 2007; 26(1): 86 - 95. [Abstract] [Full Text] [PDF]

				S. R. Tunis and S. D. Pearson Coverage Options For Promising Technologies: Medicare's 'Coverage With Evidence Development' Health Aff., September 1, 2006; 25(5): 1218 - 1230. [Abstract] [Full Text] [PDF]

				P. S. Keenan, P. J. Neumann, and K. A. Phillips Biotechnology And Medicare's New Technology Policy: Lessons From Three Case Studies Health Aff., September 1, 2006; 25(5): 1260 - 1269. [Abstract] [Full Text] [PDF]